AI Drug Safety Startup Sable Bio Secures $3.75M, Backed By Growing Pharma Adoption

The round was led by MMC Ventures, with continued support from existing investors Episode 1 Ventures and Seedcamp.

Since raising $2 million in pre-seed funding in late 2023 Sable Bio has signed commercial agreements with several pharmaceutical companies, including three of the world’s top ten pharma firms, as well as biotech and investment organisations. Over the past year, the company has generated $0.5 million in revenue, highlighting growing demand for early drug safety risk detection solutions.

Unexpected toxicity remains the leading cause of clinical trial failures costing the pharmaceutical industry billions every year. Target safety assessments rely on literature reviews preclinical testing, and expert judgment. Manual processes cannot keep pace with the growing volume of biomedical data now available to drug discovery teams.

Read Also - Belgium’s HRTech Startup Move To Happiness Raises €1 Million Funding

Sable’s platform tackles this challenge by combining multiple data sources into a single safety assessment system. Custom models analyse millions of scientific papers and reports to identify safety relevant insights while advanced analytical methods distinguish genuine safety risks from background noise.

The platform delivers prioritised findings, helping scientists detect concerns earlier and plan risk mitigation strategies.

“Drug safety remains one of the biggest bottlenecks in pharmaceutical R&D, yet it is still dominated by manual, fragmented workflows,” said Nitish Malhotra, Investor at MMC Ventures. “Sable Bio is building a genuinely differentiated safety intelligence platform - one that leading pharma teams are already using to make faster, higher-confidence decisions. We’re excited to be backing a team with a combination of deep domain expertise, strong early commercial traction, and a clear path to becoming a system of record for safety assessment.”

“The pharmaceutical industry has made tremendous strides in AI for hit identification and lead optimisation, but target safety assessment has lagged behind,” Josh Almond-Thynne co-founder and CEO. “Sable is positioned to change that by making comprehensive safety data accessible and actionable. We’re thrilled that with this funding, we can build the definitive platform for drug target safety.”

“We’ve built Sable to integrate crucial data from diverse sources" added Olly Oechsle, CTO, Sable Bio, “These datasets currently feed drug safety science, and we’re excited about expanding into other use cases to support different disciplines in drug discovery.”

Sable plans to use the new capital to expand its London-based team, accelerate product development, and integrate real-world evidence. The company is actively seeking additional partnerships with biotech, pharmaceutical, and healthtech organisations looking to strengthen their target safety capabilities.

About Sable Bio

Founded in 2023 by former BenevolentAI scientists Dr Alex de Giorgio and Dr Josh Almond-Thynne Sable Bio develops technology that helps predict drug safety risks early in development. The company combines diverse biomedical data and advanced analytics to identify potential side effects helping pharmaceutical companies reduce costly clinical trial failures and improve patient safety.